Published in Cancer J Sci Am on June 11, 1997
Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol (2008) 1.66
A comparison of prostate cancer treatments: are therapeutic implications justified? Cancer J Sci Am (1997) 1.38
Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol (2002) 0.96
Prostate cancer: 11. Alternative approaches and the future of treatment. CMAJ (1999) 0.93
Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy. Br J Cancer (2009) 0.92
Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. Oncoscience (2014) 0.81
Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. Int J Clin Oncol (2006) 0.81
The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc (2000) 0.79
Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia. Prostate Int (2013) 0.75
Laparoscopic radical prostatectomy: Oncological outcome analysis from a single-center Indian experience of 6 years. Indian J Urol (2012) 0.75
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 4.86
A microassay for cell-mediated immunity. Transplantation (1970) 4.29
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Sequence of the 16 S-23 s spacer region in two ribosomal RNA operons of Escherichia coli. J Biol Chem (1979) 4.19
Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol (1999) 3.96
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
Selective cytotoxicity of peritoneal leucocytes for neoplastic cells. Cell Immunol (1973) 3.17
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med (1968) 3.01
Plasma oxytocin levels in autistic children. Biol Psychiatry (1998) 2.77
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation (1998) 2.44
Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry (1999) 2.32
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
In vitro cytotoxicity by a nonthymus-processed lymphocyte population with specificity for a virally determined tumor cell surface antigen. J Exp Med (1972) 2.13
Surface immunoglobulin-moieties on lymphoid cells. Exp Cell Res (1970) 2.09
Intrathecal fentanyl with small-dose dilute bupivacaine: better anesthesia without prolonging recovery. Anesth Analg (1997) 2.09
Preoperative serum hCG level and intraoperative failure of laparoscopic linear salpingostomy for ectopic pregnancy. Obstet Gynecol (1998) 2.03
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines. Cancer Res (1967) 2.01
T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res (1993) 1.98
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
Bupivacaine wound instillation via an electronic patient-controlled analgesia device and a double-catheter system does not decrease postoperative pain or opioid requirements after major abdominal surgery. Anesth Analg (2001) 1.96
Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med (1987) 1.90
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
Growth and antigenic properties of a biopsy-derived Burkitt's lymphoma in thymus-less (nude) mice. Int J Cancer (1973) 1.80
Cell surface localized IgM-kappa immunoglobulin reactivity in a case of chronic lymphocytic leukaemia. Clin Exp Immunol (1970) 1.80
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer (1989) 1.74
LATE INTESTINAL STENOSIS FOLLOWING STRANGULATED HERNIA. Ann Surg (1928) 1.72
Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Anti-K562 effectors are distinct from allospecific CTL and can be generated from NK-depleted T cells. J Immunol (1979) 1.71
Meta-analysis of clinical trials as a scientific discipline. II: Replicate variability and comparison of studies that agree and disagree. Stat Med (1988) 1.70
The lymphocyte response to primary Moloney sarcoma virus tumors in BALB-c mice. Definition of the active subpopulations at different times after infection. J Exp Med (1973) 1.68
Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord (1999) 1.63
Nanomechanical measurements of a superconducting qubit. Nature (2009) 1.63
Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology (1997) 1.63
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin (2009) 1.62
Detection of cell surface antigens on monolayer cells. I. The application of immune adherence on a micro scale. Immunology (1970) 1.62
Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. J Natl Cancer Inst (1966) 1.61
Sensitivity and specificity of dipstick tests for rapid diagnosis of malaria in nonimmune travelers. J Clin Microbiol (1999) 1.59
Should peritoneal tears be routinely closed during laparoscopic total extraperitoneal repair of inguinal hernias? A reappraisal. Surg Endosc (2004) 1.59
Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg (1995) 1.56
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology (1996) 1.55
Endoscopic sphincterotomy in patients with gallbladder in situ: the influence of periampullary duodenal diverticula. Surgery (1990) 1.55
Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. J Natl Cancer Inst (1967) 1.52
Conditioned tumorigenicity of activated oncogenes. Cancer Res (1986) 1.51
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
Acute stress response and posttraumatic stress disorder in traffic accident victims: a one-year prospective, follow-up study. Am J Psychiatry (1999) 1.48
Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphcoytes. J Exp Med (1980) 1.48
Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb) (2003) 1.47
Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures. J Immunol (1980) 1.47
Studies on Murine Sarcoma Virus: antigenic characterization of Murine Sarcoma Virus induced tumor cells. Int J Cancer (1969) 1.47
Surgace IgM specificity on cells derived from a Burkitt's lymphoma. Lancet (1967) 1.46
Characteristics of new cell lines derived from Burkitt lymphomas. Cancer (1969) 1.46
A comparison between emergency and delayed endoscopic injection sclerotherapy of bleeding esophageal varices in nonalcoholic portal hypertension. J Clin Gastroenterol (1990) 1.45
Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans. Int J Cancer (1977) 1.45
The effect of anesthesia type on needle localization breast biopsy: another point of view. Am J Surg (1996) 1.45
Ventilation rates and health: multidisciplinary review of the scientific literature. Indoor Air (2011) 1.44
The forgotten indwelling ureteral stent: a urological dilemma. J Urol (1995) 1.43
Concentration of virus from water by electro-osmosis and forced-flow electrophoresis. Prep Biochem (1971) 1.43
Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med (1973) 1.42
A trap of our own making. Anesthesiology (1995) 1.41
Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol (2001) 1.41
Fluorometric quantitation of fluorescein-coupled antibodies attached to the cell membrane. Proc Natl Acad Sci U S A (1969) 1.40
[Consensus on spontaneous bacterial peritonitis in liver cirrhosis: diagnosis, treatment, and prophylaxis]. Gastroenterol Hepatol (2001) 1.40
Emergency aortorenal revascularization during salvage retroperitoneal lymph node dissection. J Urol (1999) 1.39
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A (1986) 1.38
Treatment of Burkitt's lymphoma. Lancet (1968) 1.37
Synergistic or antgonistic effect of different antibody concentrations on in vitro lymphocyte cytotoxicity in the Moloney sarcoma virus system. J Exp Med (1972) 1.36
Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker. Blood (1977) 1.35
Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s). J Immunol (1975) 1.34
Selection of an immunoresistant Moloney lymphoma subline with decreased concentration of tumor-specific surface antigens. J Natl Cancer Inst (1968) 1.32
Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol Psychiatry (2013) 1.30
Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance. Am J Transplant (2009) 1.29
Hypersensitivity reactions at tumor sites. Cancer Res (1969) 1.26
Complications of nephron sparing surgery for renal tumors. J Urol (1994) 1.24
Activated T cells in the synovial fluid of arthritic patients: characterization and comparison with in vitro activated human and murine T cells in cooperation with monocytes in cytotoxicity. J Immunol (1979) 1.24
Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol (1999) 1.24
Human tumour--lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer (1977) 1.24
Human thyroglobulin and thyroid extract as specific stimulators of sensitized lymphocytes. J Clin Endocrinol Metab (1971) 1.22
Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 1.20
Oncogene activation and tumor progression. Carcinogenesis (1984) 1.16
Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi. Ann Surg (1990) 1.13
Temperature-sensitive micrometer-thick layers of hyaluronan grafted on microspheres. J Am Chem Soc (2006) 1.13
Characterization of immunoglobulin structures from the surface of chronic lymphocytic leukemia cells. J Exp Med (1971) 1.12
Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int J Cancer (1994) 1.12
Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol (1997) 1.11
Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res Treat (1999) 1.11
Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol (1983) 1.11
Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother (1990) 1.11
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol (1997) 1.11
Human leukemia-associated anti-nuclear reactivity. Proc Natl Acad Sci U S A (1974) 1.09
Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cancer (1982) 1.09
Antibody response and leukemia development in mice inoculated neonatally with the Moloney virus. Cancer Res (1965) 1.08
Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol (1994) 1.08